These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: First report in a dog model of atopic dermatitis: expression patterns of protease-activated receptor-2 and thymic stromal lymphopoietin.
    Author: Kim HJ, Ahrens K, Park HM, Marsella R.
    Journal: Vet Dermatol; 2015 Jun; 26(3):180-5, e36-7. PubMed ID: 25940870.
    Abstract:
    BACKGROUND: Protease-activated receptor (PAR)-2 plays a crucial role in inflammation and the skin barrier. Protease-activated receptor-2 is activated by proteolytic enzymes of allergens and stimulates thymic stromal lymphopoietin (TSLP), promoting T-helper 2 cytokines. In humans with atopic dermatitis (AD), increased expression of PAR-2 and TSLP has been reported. HYPOTHESIS/OBJECTIVES: To compare the pattern of staining of PAR-2 and TSLP between normal and atopic beagle dogs. The hypothesis tested was that increased expression is present in atopic dog skin compared with healthy control skin. ANIMALS: Eight atopic and five normal dogs were challenged for 3 days with house dust mites. METHODS: Skin biopsies were taken to measure the intensity, distribution, integrity and cell staining pattern on days 0, 3 and 10, both objectively and subjectively. Clinical signs were scored and compared between groups. RESULTS: Atopic dogs showed a significant increase in clinical scores on days 3 (peak of challenge) and 10 (resolution) and a significant condensed staining pattern for TSLP in the stratum basale at all times in comparison to normal dogs. They showed a significant patchy pattern for PAR-2 on days 0 and 3 and for TSLP at all times compared with normal dogs. The intensity itself was not significantly increased in atopic dogs compared with normal animals for both PAR-2 and TSLP. CONCLUSIONS AND CLINICAL IMPORTANCE: These preliminary findings do not confirm a difference in the amount of expression but rather in its pattern. Studies using PAR-2 or TSLP inhibitors could shed light on their clinical relevance.
    [Abstract] [Full Text] [Related] [New Search]